September 18, 2017 06:59 AM EDT
Financing
Startups

Cut loose from Bio­gen buy­out op­tion, Rodin preps for an ear­ly-stage shot at Alzheimer’s

John Carroll

Editor & Founder

Af­ter qui­et­ly scrap­ping a $485 mil­lion buy­out op­tion held by Bio­gen, Cam­bridge, MA-based Rodin Ther­a­peu­tics has lined up a $27 mil­lion round to get its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times